[144] IQVIA Holdings Inc. SEC Filing

Rhea-AI Filing Summary

Form 8-K – Item 5.07: 2025 Annual Meeting Voting Results

Rein Therapeutics, Inc. (Nasdaq: RNTX) filed an 8-K covering the July 23 2025 reconvened Annual Meeting. Two routine governance items were approved:

• Director election: William C. Fairey was elected Class II director through the 2028 AGM with 7,661,847 votes for and 1,621,599 withheld; no broker non-votes.
• Say-on-pay: Shareholders backed the company’s executive compensation on a non-binding basis with 8,325,803 votes for (≈94%), 146,938 against, and 810,705 abstentions; no broker non-votes.

No additional proposals, financial results, guidance, or strategic actions were disclosed. The filing is informational and does not indicate changes to operations, capital structure, or outlook.

Insights

Corporate Governance Analyst

TL;DR – Routine vote results; no material impact.

The director was re-elected and executive pay received strong (~94%) support, signaling shareholder confidence in current leadership. Both outcomes are customary and expected for a company of Rein’s size. Because there are no new strategic directives, financial metrics, or capital actions, the filing is largely procedural. Investors should view the impact as neutral; governance stability continues, but nothing herein alters valuation or risk profile.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Morgan Stanley Smith Barney LLC Executive Financial Services 1 New York Plaza 8th Floor New York NY 10004	549	105149.97	170000000	07/23/2025	NYSE

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	07/28/2024	Restricted Stock	Issuer			65	07/28/2024	Not Applicable
Common	02/11/2022	Restricted Stock	Issuer			13	02/11/2022	Not Applicable
Common	01/28/2025	Performance Shares	Issuer			265	01/28/2025	Not Applicable
Common	05/16/2022	Restricted Stock	Issuer			162	05/16/2022	Not Applicable
Common	02/10/2025	Restricted Stock	Issuer			22	02/10/2025	Not Applicable
Common	02/10/2023	Restricted Stock	Issuer			22	02/10/2023	Not Applicable

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Nothing to Report

144: Remarks and Signature

Remarks

Date of Notice

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What did Rein Therapeutics (RNTX) disclose in its July 23 2025 Form 8-K?

The company reported voting results from its 2025 Annual Meeting, covering a director election and advisory say-on-pay approval.

Was the director nominee elected at the Rein Therapeutics 2025 AGM?

Yes. William C. Fairey was elected as a Class II director, receiving 7,661,847 votes for and 1,621,599 withheld.

How much support did the say-on-pay proposal receive from RNTX shareholders?

Approximately 94% of votes cast (8,325,803) favored the company’s executive compensation program.

Were there any broker non-votes reported for the RNTX meeting items?

No. Both proposals recorded zero broker non-votes.

Does the filing contain any financial results or guidance updates for Rein Therapeutics?

No. The 8-K is limited to voting outcomes and provides no financial or operational updates.

Is this 8-K expected to affect Rein Therapeutics' stock price?

Likely not. The disclosed matters are routine governance items with no direct financial impact.